DASATINIB, a drug commonly
used to treat leukaemia, is showing
promise as a treatment that could
slow the muscle-wasting condition,
Duschenne Muscular Dystrophy.
Working by blocking chemical
signals that stimulate cancer cell
growth, researchers at University
of Scheffield found the same drug
could also switch off similar signals
in a protein commonly implicated in
Duchenne muscular dystrophy.
As Dasatinib has already been
cleared for clinical use, researchers
are hoping progress can be quickly
made towards treatment for DMD.The above article was sent to subscribers in Pharmacy Daily's issue from 07 Jan 16 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 07 Jan 16
THE role and significance of community pharmacy in regional areas was a key focus of discussion for the Nationals leader David Littleproud during last week’s visit to Orana Mall Pharmacy as part of a regional tour.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.